{"generic":"Rabies Immune Globulin","drugs":["Bayrab","HyperRAB S\/D","Imogam Rabies-HT","Rabies Immune Globulin"],"mono":{"0":{"id":"501670-s-0","title":"Generic Names","mono":"Rabies Immune Globulin"},"1":{"id":"501670-s-1","title":"Dosing and Indications","sub":{"0":{"id":"501670-s-1-4","title":"Adult Dosing","mono":"<b>Rabies, Postexposure; Prophylaxis:<\/b> 20 International Units\/kg IM for 1 dose in conjunction with rabies vaccine "},"1":{"id":"501670-s-1-5","title":"Pediatric Dosing","mono":"<b>Rabies, Postexposure; Prophylaxis:<\/b> 20 International Units\/kg IM for 1 dose in conjunction with rabies vaccine "},"3":{"id":"501670-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Rabies, Postexposure; Prophylaxis<br\/>"}}},"3":{"id":"501670-s-3","title":"Contraindications\/Warnings","sub":[{"id":"501670-s-3-9","title":"Contraindications","mono":"repeated doses, should not be administered once vaccine treatment has been initiated; potential for interference with maximum active immunity expected from vaccine (Imogam(R) Rabies-HT) <br\/>"},{"id":"501670-s-3-10","title":"Precautions","mono":"<ul><li>bleeding disorders, preexisting; may result in bleeding complications due to intramuscular route of vaccine<\/li><li>concomitant use with live vaccines, such as measles, mumps, polio, or rubella; should not be used within 3 months of rabies immunoglobulin<\/li><li>human plasma product; infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>intramuscular use only; should not be administered intravenously because of potential for serious reactions<\/li><li>isolated immunoglobulin A deficiency; may increase risk for developing antibodies to IgA and for anaphylactic reactions with subsequent administration of IgA-containing blood products<\/li><li>repeated doses, should not be administered once vaccine treatment has been initiated; potential for interference with maximum active immunity expected from vaccine (HyperRab(TM) S\/D)<\/li><li>systemic allergic reaction to human immune globulin preparation, history<\/li><li>thrombocytopenia, preexisting; may result in bleeding complications due to intramuscular route of vaccine<\/li><li>report suspected transmission of infection from HyperRAB(TM) S\/D to Talecris Biotherapeutics at 1-800-520-2807 and from Imogam(R) Rabies-HT to Sanofi Pasteur at 1-800-822-2463<\/li><\/ul>"},{"id":"501670-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"501670-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"501670-s-4","title":"Drug Interactions","sub":{"2":{"id":"501670-s-4-15","title":"Moderate","mono":"<ul><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"501670-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (conventional formulation, 63%; heat-treated formulation, 25%), Injection site pain (conventional formulation, 100%; heat-treated formulation, 50%)<\/li><li><b>Neurologic:<\/b>Headache (conventional formulation, 50%; heat-treated formulation, 69%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis (rare)<br\/>"},"6":{"id":"501670-s-6","title":"Drug Name Info","sub":{"0":{"id":"501670-s-6-17","title":"US Trade Names","mono":"<ul><li>Bayrab<\/li><li>Imogam Rabies-HT<\/li><li>HyperRAB S\/D<\/li><\/ul>"},"2":{"id":"501670-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"501670-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"501670-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"501670-s-7","title":"Mechanism Of Action","mono":"Systemic: Following intramuscular administration, rabies immune globulin provides immediate passive antibodies for a short period of time. This protects the patient until the patient can produce active antibodies from the rabies vaccine. <br\/>"},"9":{"id":"501670-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>if anatomically possible, thoroughly infiltrate the full dose in the area around the wound; any remaining volume may be given IM (using a separate needle) at a site distant from vaccine administration; for HyperRAB S\/D(R), may administer the remainder into the deltoid muscle of the upper arm or lateral thigh muscle; avoid the gluteal region due to risk of injury to sciatic nerve<\/li><li>do not mix in same syringe as vaccine<\/li><\/ul>"},"10":{"id":"501670-s-10","title":"Monitoring","mono":"clinical signs and symptoms of rabies, rabies antibody titer<br\/>"},"11":{"id":"501670-s-11","title":"How Supplied","mono":"<ul><li><b>HyperRAB S\/D<\/b><br\/>Intramuscular Solution: 150 IU\/ML<br\/><\/li><li><b>Imogam Rabies-HT<\/b><br\/>Intramuscular Solution: 150 IU\/ML<br\/><\/li><\/ul>"},"13":{"id":"501670-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines up to 3 mo after receiving this drug, unless approved by healthcare professional.<\/li><li>Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>This drug may cause headache or fever.<\/li><\/ul>"}}}